Delivery Order SPE2DB22D2206-SPE2DB25FHD76
Award Date
5/28/25
Potential Completion Date
5/29/25
Potential Value
$2.1K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of HEMABATE 250 MCG/ML AMPUL/ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on December 6, 2024 with a ceiling value of $4,586.44. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of December 9, 2024. This award is not designated as a set-aside...
This is a federal contract awarded by the Defense Logistics Agency (DLA), a defense agency, to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a ceiling value of $2,543.70 and a firm fixed price pricing type. The contract is for HEMABATE 250 MCG/ML AMPUL/ML, a pharmaceutical product, with a period of performance through June 6, 2025. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract...
This federal contract award is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, to the Defense Logistics Agency (DLA), a defense agency. The $1,284.14 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on January 31, 2025, with a completion date of February 3, 2025. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is a for-profit organization...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $2,666.41, is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product. The contract is a firm fixed-price delivery order with an ultimate completion date of April 18, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a Firm Fixed Price Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of HEMABATE 250 MCG/ML AMPULML medical products. The contract has a ceiling value of $3,567.20 and an ultimate completion date of June 11, 2025. It is not designated as a set-aside contract. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a ceiling value of $1,656.93 and a performance period through May 28, 2025. The contract is not set-aside and was awarded on May 27, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite...
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical distribution company. The contract is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a potential value of $5,486.15 and a completion date of January 29, 2024. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp holds an Indefinite...
This federal contract award, valued at $7,061.26, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of HEMABATE 250 MCG/ML AMPUL/ML, a pharmaceutical product, with a completion date of January 23, 2024. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, including the Department of Defense (DoD) and Veterans Affairs...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distributor AmerisourceBergen Corporation. The $8,777.92 firm fixed price delivery order is for the supply of HEMABATE 250 MCG/ML AMPULML, a prescription medication. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, valued at up to $999,999,999.00 and running through...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of HEMABATE 250 MCG/ML ampules. The award has a ceiling value of $2,686.73 and an ultimate completion date of August 9, 2024. The contract is not associated with any set-aside. AmerisourceBergen Drug Corp, a major pharmaceutical distributor, will provide the required medical supplies through this delivery order, which is part of a larger Indefinite Delivery...